Paul Howarth

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 130 citations · Full text

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Jacob Sands, Myung‐Ju Ahn, Aaron Lisberg et al. · Journal of Clinical Oncology · 2025 · 66 citations · Full text

Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

David Planchard, Po‐Hao Feng, Nina Karaseva et al. · ESMO Open · 2021 · 61 citations · Full text

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with <i>EGFR</i>-mutant, <i>MET</i>-driven (<i>MET</i>+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

Geoffrey R. Oxnard, Mireille Cantarini, Paul Frewer et al. · Journal of Clinical Oncology · 2019 · 36 citations

Central Fish, Disease Progression, Pathology +19

A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Myung‐Ju Ahn, Aaron Lisberg, Yasushi Goto et al. · Journal of Thoracic Oncology · 2025 · 22 citations